Savara announces the rare lung disease, autoimmune pulmonary alveolar proteinosis (apap), is highlighted on a new episode of “the balancing act®” airing on lifetime® tv

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that a new episode of the balancing act®, sponsored by savara and featuring autoimmune pulmonary alveolar proteinosis (apap), is airing on lifetime tv's behind the mystery™ a recurring series on the balancing act® television show devoted to advocating for people with rare and genetic diseases. the episode centers on the diagnostic.
SVRA Ratings Summary
SVRA Quant Ranking